Halozyme Therapeutics (HALO): Evaluating Valuation Following New ENHANZE Partnership With Merus

Halozyme Therapeutics (HALO) just signed a new global collaboration with Merus N.V., allowing Merus to use the ENHANZE drug delivery platform for development and potential commercialization of a novel bispecific antibody. This agreement highlights ongoing interest in Halozyme's technology and its ability to broaden long-term revenue sources through strategic partnerships.

See our latest analysis for Halozyme Therapeutics.

Halozyme shares have gained momentum recently, with an 11.3% one-month share price return and a solid 51.3% year-to-date gain. This signals growing confidence in the company's growth path and collaborative strategy amid active deal-making and ongoing industry attention. Over the longer term, total shareholder returns remain robust, reflecting both operational execution and increased licensing activity.

If Halozyme's recent partnership activity caught your attention, you might want to broaden your search and discover See the full list for free.

With shares up sharply this year and growing interest from industry partners, the key question becomes whether Halozyme Therapeutics still offers room for upside or if the current market price already reflects its next phase of growth.

Most Popular Narrative: 4% Undervalued

The most widely followed valuation narrative places Halozyme Therapeutics' fair value just above its latest closing price. This suggests the stock may offer a slight advantage over current market levels for those who agree with these consensus expectations.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (for example, DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Read the complete narrative.

This valuation narrative is built on a series of aggressive forecasts and sector-defining shifts. Want to see which future profit targets and bullish expansion assumptions make up the backbone of this fair value? Only the full narrative reveals the bold calculations behind this high-stakes price call.

Result: Fair Value of $76 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing patent litigation and revenue concentration among a handful of key partners could quickly shift the optimism underpinning Halozyme's current valuation.

Find out about the key risks to this Halozyme Therapeutics narrative.

Build Your Own Halozyme Therapeutics Narrative

If you see things differently or want to analyze the numbers yourself, it's easy to craft your own perspective on Halozyme in just a few minutes. Do it your way

A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Take action on your next smart investment move. Don’t just stop at Halozyme when so many other compelling opportunities are out there right now.

• Spot future leaders in advanced computing when you scan these 28 quantum computing stocks, bringing quantum innovation into real-world markets today.
• Boost your passive income by checking out these 15 dividend stocks with yields > 3%, offering higher-than-average yields to steady your portfolio through any market cycle.
• Ride the AI momentum and get inspired by these 25 AI penny stocks, at the forefront of artificial intelligence breakthroughs and rapid industry adoption.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com